Table 3.
Univariate and multivariate cox analysis of the overall survival for patients with oropharyngeal carcinoma (OPC) and Hypopharyngeal carcinoma (HPC) in the training groups.
| Covariate | OPC | HPC | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| HPV status | ||||||||
| HPV (-) | – | – | – | – | – | – | – | – |
| HPV (+) | 0.36 (0.32–0.41) | <0.001 | 0.49 (0.43–0.56) | <0.001 | 0.51 (0.32–0.79) | 0.003 | 0.61 (0.38–0.97) | 0.038 |
| Age | ||||||||
| 18–49 | – | – | – | – | – | – | – | – |
| 50–69 | 1.47 (1.18–1.85) | 0.001 | 1.35 (1.08–1.70) | 0.010 | 1.21 (0.58–2.49) | 0.612 | 1.27 (0.61–2.67) | 0.524 |
| >=70 | 3.12 (2.44–3.98) | <0.001 | 2.33 (1.81–3.00) | 0.218 | 1.80 (0.85–3.84) | 0.126 | 2.13 (0.97–4.70) | 0.060 |
| Race | ||||||||
| Black | – | – | – | – | – | – | – | – |
| White | 0.47 (0.39–0.57) | <0.001 | 0.92 (0.76–1.11) | 0.395 | 0.55 (0.37–0.83) | 0.005 | 0.67 (0.43–1.06) | 0.087 |
| Other# | 0.63 (0.44–0.89) | 0.009 | 1.08 (0.75–1.54) | 0.678 | 0.67 (0.34–1.34) | 0.259 | 0.62 (0.29–1.33) | 0.222 |
| Unknown | 0.15 (0.02–1.05) | 0.056 | 0.29 (0.04–2.08) | <0.001 | ||||
| Gender | ||||||||
| Male | – | – | – | – | – | – | – | – |
| Female | 1.40 (1.20–1.64) | <0.001 | 1.13 (0.96–1.33) | 0.136 | 1.26 (0.83–1.89) | 0.278 | – | – |
| Marital status | ||||||||
| Married | – | – | – | – | – | – | – | – |
| Non-married | 2.33 (2.05–2.65) | <0.001 | 1.78 (1.55–2.03) | <0.001 | 1.56 (1.10–2.22) | 0.014 | 1.27 (0.85–1.90) | 0.242 |
| Unknown | 2.33 (2.05–2.65) | 0.001 | 1.38 (1.04–1.85) | 0.028 | 1.63 (0.87–3.05) | 0.126 | 1.60 (0.83–3.10) | 0.161 |
| Grade | ||||||||
| Grade I–II | – | – | – | – | – | – | – | – |
| Grade III–IV | 0.60 (0.53–0.70) | <0.001 | 0.68 (0.59–0.79) | <0.001 | 0.89 (0.61–1.29) | 0.537 | – | – |
| Unknown | 0.86 (0.73–1.01) | 0.059 | 0.86 (0.73–1.02) | 0.080 | 0.97 (0.62–1.53) | 0.900 | – | – |
| T stage | ||||||||
| T1 | – | – | – | – | – | – | – | – |
| T2 | 1.51 (1.24–1.85) | <0.001 | 1.47 (1.20–1.81) | <0.001 | 2.60 (1.02–6.61) | 0.045 | 2.46 (0.94–6.44) | 0.067 |
| T3 | 3.12 (2.53–3.84) | <0.001 | 2.53 (2.03–3.15) | <0.001 | 3.48 (1.38–8.83) | 0.008 | 3.84 (1.47–10.00) | 0.006 |
| T4 | 5.67 (4.66–6.90) | <0.001 | 3.85 (3.11–4.75) | <0.001 | 5.59 (2.23–14.02) | <0.001 | 5.75 (2.22–14.85) | <0.001 |
| N stage | ||||||||
| N0 | – | – | – | – | – | – | – | – |
| N1 | 0.87 (0.70–1.08) | 0.212 | 1.10 (0.88–1.38) | 0.403 | 1.15 (0.69–1.93) | 0.595 | 1.44 (0.83–2.50) | 0.192 |
| N2 | 0.97 (0.82–1.16) | 0.779 | 1.36 (1.13–1.64) | 0.001 | 1.3 (0.86–1.98) | 0.219 | 1.60 (1.00–2.55) | 0.050 |
| N3 | 2.05 (1.57–2.68) | <0.001 | 2.05 (1.54–2.72) | <0.001 | 2.51 (1.19–5.28) | 0.015 | 4.06 (1.80–9.15) | 0.001 |
| M stage | ||||||||
| M0 | – | – | – | – | – | – | – | – |
| M1 | 5.63 (4.58–6.93) | <0.001 | 3.06 (2.45–3.82) | <0.001 | 2.57 (1.47–4.49) | 0.001 | 1.31 (0.70–2.47) | 0.4025 |
| Surgery for primary site | ||||||||
| No | – | – | – | – | – | – | – | – |
| Yes | 0.39 (0.33–0.45) | 0.51 (0.43–0.6) | 0.58 (0.36–0.94) | 0.026 | 0.53 (0.32–0.89) | 0.016 | ||
| Unknown | 1.38 (0.19–9.78) | 0.749 | 2.37 (0.33–17.11) | 0.394 | – | – | – | – |
| Radiotherapy | ||||||||
| No | – | – | – | – | – | – | – | – |
| Yes | 0.41 (0.35–0.48) | <0.001 | 0.44 (0.37–0.52) | <0.001 | 0.50 (0.32–0.76) | 0.002 | 0.59 (0.35–1.00) | 0.048 |
| Chemotherapy | ||||||||
| No | – | – | – | – | – | – | – | – |
| Yes | 0.76 (0.66–0.87) | <0.001 | 0.65 (0.55–0.76) | <0.001 | 0.59 (0.40–0.86) | 0.006 | 0.49 (0.30–0.79) | 0.004 |
#American Indian/AK Native, Asian/Pacific Islander.
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinomas; AJCC, American Joint Committee on Cancer.
The bold values indicated that P-value was less than 0.05 and the difference was statistically significant.